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Abstract
Rotavirus is a major cause of gastroenteritis in children, with infection typically inducing high
levels of protective antibodies. Antibodies targeting the middle capsid protein VP6 are par-
ticularly abundant, and as VP6 is only exposed inside cells, neutralisation must be post-
entry. However, while a system of poly immune globulin receptor (pIgR) transcytosis has
been proposed for anti-VP6 IgAs, the mechanism by which VP6-specific IgG mediates pro-
tection remains less clear.
We have developed an intracellular neutralisation assay to examine how antibodies neu-
tralise rotavirus inside cells, enabling comparison between IgG and IgA isotypes. Unexpect-
edly we found that neutralisation by VP6-specific IgG was much more efficient than by VP6-
specific IgA. This observation was highly dependent on the activity of the cytosolic antibody
receptor TRIM21 and was confirmed using an in vivo model of murine rotavirus infection.
Furthermore, mice deficient in only IgG and not other antibody isotypes had a serious deficit
in intracellular antibody-mediated protection.
The finding that VP6-specific IgG protect mice against rotavirus infection has important
implications for rotavirus vaccination. Current assays determine protection in humans pre-
dominantly by measuring rotavirus-specific IgA titres. Measurements of VP6-specific IgG
may add to existing mechanistic correlates of protection.
Author summary
Rotavirus is the leading cause of gastroenteritis in children worldwide. Effective rotavirus
vaccines have been available for over a decade, but detailed understanding of the immune
response to rotavirus infection is essential for further improvement of vaccines. High lev-
els of antibodies are made in response to infection, especially antibodies targeting the
inner capsid protein VP6, but while both IgA and IgG isotypes are produced, previous
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work has focused predominantly on VP6-specific IgA. In this study we sought to evaluate
the importance of VP6-specific IgG in rotavirus protection.
As VP6-specific antibodies target incomplete rotavirus particles inside cells, we devel-
oped a new assay to examine how antibodies neutralise rotavirus intracellularly. We
showed that neutralisation by VP6-specific IgG was much more efficient than VP6-spe-
cific IgA, due to the activity of the cytosolic antibody receptor TRIM21. This was con-
firmed using a mouse model of rotavirus infection. Furthermore, mice with normal IgA
levels but deficient in IgG had a serious deficit in intracellular antibody-mediated
protection.
Our finding that VP6-specific IgG protect mice against rotavirus infection may be
valuable for predicting whether new rotavirus vaccines will work. Current assays to deter-
mine protection in humans focus on measuring rotavirus-specific IgA titres. We propose
that including measurements of VP6-specific IgG may improve knowledge on correlates
of protection.
Introduction
Species A rotaviruses are a major cause of acute gastroenteritis in infants and young children
under 5 years of age worldwide [1]. Live attenuated rotavirus vaccines, licensed in 2006, have
been introduced with good efficacy and effectiveness in> 100 countries [2]. Antibodies are
rapidly generated in response to both natural infection and vaccination, and have been shown
to be essential for protection against future rotavirus-associated disease. However, the precise
nature of this protection is poorly understood, since rotavirus-specific antibodies of different
isotypes (IgG or IgA) target a diverse range of viral proteins [3].
Rotavirus is a triple-layered particle, and a large body of evidence indicates that antibodies
targeting the VP6 protein of the middle capsid layer play a key role in protection against rota-
virus infection. VP6-specific antibodies are produced to high titres in response to rotavirus
infection or vaccination [4,5], and mice experimentally infected with rotavirus are protected
by passive transfer of anti-VP6 antibodies [6,7] or anti-VP6 nanobodies [8]. Furthermore, a
number of VP6-based vaccine approaches show induction or enhancement of protective
immunity [9–13].
The mechanisms by which VP6 antibodies mediate protection have yet to be fully charac-
terised. VP6 is only exposed after the triple-layered viral particle has entered the cell and the
outer layer containing VP4 and VP7 has been uncoated to release the double-layered particle
(DLP) [14,15]. This strongly suggests that antibodies targeting VP6 act intracellularly. Previous
studies have shown that upon binding to DLPs, some anti-VP6 monoclonal antibodies inhibit
transcription [7,16–18]. However, although additional mechanisms of neutralisation inside
cells have been postulated [7], these have not been explored in detail. We have recently charac-
terised TRIM21 as a novel cytoplasmic antibody receptor [19,20], and therefore aimed to
investigate whether TRIM21 could be involved in antibody-mediated rotavirus neutralisation
inside cells.
Following natural infection in mice and humans, it is known that antibodies produced to
target VP6 are of both IgA and IgG isotypes [21–23]. To be functional, these antibodies must
have a means of co-localising with DLPs in the cytoplasm. For IgA isotypes, co-localisation has
been shown to occur following transcytosis of IgA in the gut epithelia [6,7], and a role for the
poly-immunoglobulin receptor (pIgR) has been demonstrated [18,24,25]. However, the mech-
anism of cellular entry for IgG from the circulation into epithelia is pinocytosis, not receptor-
mediated, and therefore is expected to occur at a lower rate [26]. Since any potential activity of
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this isotype has generally been overlooked, we wanted to compare and contrast the activity of
both IgA and IgG VP6-specific antibodies in vitro and in vivo.
Due to the intracellular activity of VP6-specific antibodies, there is no high-throughput
functional assay to measure their activity. A simple assay to measure VP6-mediated intracellu-
lar neutralisation in vitro would be a valuable tool to study interactions between VP6-specific
antibodies of IgA and IgG subtypes with subviral particles.
In this study we present an in vitro assay that can efficiently measure intracellular neutrali-
sation by VP6-specific antibody of any isotype. Using this assay, we show that VP6-specific
antibodies utilize multiple mechanisms to block rotavirus replication. By extending this
approach to in vivo infections in a mouse model we show that IgG plays an important role in
protection.
Materials and methods
Cells and viruses
MA104 African green monkey fetal kidney cells (PHE culture collection) and immortalised
murine embryonic fibroblasts (MEFs, described in [27]) from wild type and TRIM21 knock-
out mice were maintained in DMEM supplemented with 10% fetal calf serum (FCS) and 100 I.
U./ml penicillin and 100 mg/ml streptomycin. Following infection with rotavirus, cells were
kept in serum-free medium, supplemented with trypsin (TPCK-treated, LS003740, Worthing-
ton Biochemical) at a final concentration of 1μg/ml.
Tissue culture-adapted simian rotavirus SA11 (G3P[1]) was used, propagated in MA104
cells as previously described [28]. Two murine rotavirus (G16P[3]) strains were used, propa-
gated in neonatal mice; the EDIM strain was a kind gift from L. Svensson, and the EMcN strain
was a kind gift from M. McNeal. All viral particles were activated with trypsin (as above) at
10μg/ml for 30 minutes at 37˚C prior to in vitro infections.
Antibody-mediated intracellular neutralisation assay
To rapidly introduce antibodies into cells, 2μl total volume of antibody or serum at a range of
concentrations were electroporated using 2 pulses of 1400V, 20 pulse width, into 3 x 105 cells
suspended in 13μl Neon1 Resuspension buffer R using the Neon1 Transfection System
(Thermo Fisher Scientific). Cells were then resuspended in 330μl antibiotic-free media con-
taining 10% FCS, before being added to the wells of a 96 well plate (in triplicate per test, 100μl
per well). Cells were incubated at 37˚C for 4 hours to become adherent to the plate and then
washed once with PBS to remove any extracellular antibody. Next, 1000 fluorescent focus
forming units (FFFU) virus in 100μl serum-free medium were added to each well. After 1
hour, an additional 50μl complete DMEM were added to each well, and infection was allowed
to proceed for 16 hours at 37˚C. For proteasome inhibition experiments, 1μM MG132 (Sigma)
was added to wells 2 hours prior to infection, and maintained in media for 4 hours post-
infection.
Extracellular neutralisation assay
Serial dilutions of antibodies from 800ng starting amount in 12.5μl serum-free medium were
incubated with 1000 FFFU trypsin-activated rotavirus in a 1:1 mixture for 1 hour at 37˚C. The
antibody-virus mixture was then diluted 1:10 in serum-free medium, and 100μl added in tripli-
cate to MA104 cells seeded at 5 x 104 cells per well of a 96 well plate. After 1 hour, an additional
50μl complete DMEM was added to each well. Infection then proceeded for 16 hours at 37˚C.
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Rotavirus quantification
Quantification of rotavirus was achieved using a fluorescent focus forming assay [28]. In brief,
after a 16 hour infection as described above, medium was removed from plates, and plates
were fixed with 1:1 methanol:acetone at -20˚C for 20 minutes. Wells were then blocked with
100μl PBS—2%FCS for 20 minutes at room temperature. Primary antibody (Sheep polyclonal
anti-rotavirus antibody, PA1-85845, Thermo Fisher Scientific) diluted 1:500 in PBS—2%FCS
was added for 1 hour at room temperature. After 3 washes with PBS, 25μl Alexa-Fluor
488-conjugated anti-sheep IgG (Invitrogen) diluted 1:500 in PBS—2%FCS and compound
Hoechst 33342 (20mM, Thermo Fisher Scientific) diluted 1:1000 were added to each well and
plates were incubated at room temperature for 1 hour. Wells were washed three times with
PBS, prior to imaging using a Nikon Eclipse Ti microscope and counting of fluorescent foci
was performed using Nikon NIS-Elements version 4.4 software. For neutralisation experi-
ments, counts of foci in wells with and without antibody were compared.
Immunofluorescence
Monoclonal antibody (mouse) was electroporated into MEF cells as described above, then
cells were plated on cover slips (Corning BioCoat, Poly-D-Lysine, 12 mm) in 24-well plates
and allowed to adhere for 4 hours. Cells were infected with rotavirus at MOI 20 for 1 hour,
then washed three times with PBS and fixed in 4% paraformaldehyde (PFA) (Thermo Fisher
Scientific). Cells were permeabilized in 0.1% Triton X-100 in PBS (PBS-X) and blocked with
5% BSA (Thermo Fisher Scientific) in PBS-X. The electroporated antibody in cells was first
stained with Alexa-Fluor 488-conjugated anti-mouse IgG (Invitrogen), then DLPs were
stained with an anti-VP6 MAb conjugated to Alexa-Fluor 568. Antibody conjugation was per-
formed according to manufacturer’s instruction (Thermo Fisher Scientific). Hoechst 33342
diluted 1:1000 was added simultaneously with the final antibody incubation step. Both primary
and secondary antibodies were diluted in 5% BSA-PBS-X, and incubated with cells for 1 hour
at room temperature. After each antibody incubation, cells were washed three times with PBS,
then once with water. The cover slips were carefully dried and adhered to slides using mount-
ing medium (ProLong Diamond Antifade Mountant, ThermoFisher Scientific).
Preparation and purification of rotavirus double-layered virus particles
(DLPs)
The SA11 strain of rotavirus was inoculated onto cell culture monolayers of MA104 cells at an
MOI of 0.1. DLPs were then purified according to previously published protocol [28]. In brief,
when cell monolayers exhibited complete cytopathic effect, cultures were subjected to freeze-
thawing three times. Virus was sedimented by ultracentrifugation in a Beckman ultracentri-
fuge at 100,000 x g for 1.5 hours at 4˚C. The resulting pellet was resuspended in TNC buffer
(20mM Tris-HCl, 100mM NaCl and 1mM CaCl2, pH8.0) and the cellular debris was removed
by addition of Vertrel XF (Sigma) and vortexing. The suspension was then centrifuged at 4,100
x g for 30 minutes at 4˚C to separate virus from cell debris. Virus particles were sedimented by
ultracentrifugation at 100,000 x g for 1.5 hours. Final purification of the pelleted virus was
achieved by isopycnic CsCl gradient ultracentrifugation at 110,000 x g for 18 hours. Viral
bands containing triple layered particles (TLPs) and DLPs were collected by needle puncture
from the ultracentrifuge tube, and virus suspensions were dialysed against TNC buffer over-
night at 4˚C. DLPs were quantitated using a NanoDrop spectrophotometer (Thermo Scien-
tific), and purity was visualized by SDS-PAGE and Coomassie blue staining (Instant Blue,
Expedeon).
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Generation of CRISPR knockout cell lines
Generation of knockout MA104 cell lines was achieved by electroporation of Cas9/gRNA ribo-
nucleoprotein complexes (Cas9-RNP) along with single stranded guide RNAs. TracrRNA and
crRNA against TRIM21 were obtained from IDT. TracrRNA-crRNA complexes were assem-
bled by incubating at 95˚C for 5 min followed by cooling on the benchtop to 20˚C. The RNA
complexes were mixed with recombinant Cas9 protein at a molar ratio of 1.2:1 and incubated
at 37˚C for 10 min to form Cas9 RNP complexes. 50 pmol of Cas9-RNP complex was intro-
duced into 8 × 105 MA104 cells using the Neon Transfection System (Invitrogen) with a setting
of 2 pulses of 1400 V for 20 ms. 48 hr post electroporation, the cells were cloned by fluores-
cence-activated cell sorting into 96-well plates (1 cell/well). Knockout (KO) mutations were
confirmed by western blotting for TRIM21 protein, and loss of function was confirmed by a
‘Trim-Away’experiment as described in [29]; in brief anti-IKKα antibody (Abcam) was elec-
troporated into WT and KO cells, then 3 hours later cells were lysed and probed by western
blot for IKKα.
Antibody production and purification
Hybridoma cell lines expressing monoclonal antibodies (MAb) recognizing rotavirus proteins
were cultured in RPMI media supplemented with low IgG serum (Hyclone, GE Healthcare).
The anti-VP6 IgA hybridoma 7D9 was a kind gift from H. Greenberg and J.E. Crowe. Hybrid-
oma supernatant was collected and antibodies purified using an AKTA chromatography sys-
tem (GE Healthcare). A protein G-agarose column was used for hybridomas producing
VP4-specific IgG antibodies (1A9 and 7A12, first described in [30]) and a protein L-agarose
column was used to purify VP6-specific IgA antibodies (7D9 and 2C5, first described in
[6,30]). In brief, supernatant of hybridoma cultures was applied to the appropriate column at
4˚C, then following washing with 5 column volumes of PBS, antibody was eluted with 0.1M
glycine buffer pH 2.0 and immediately pH adjusted with 1M Tris-HCl buffer pH 9.0. Coomas-
sie blue staining of an SDS-PAGE gel confirmed purification of antibody, and following dialy-
sis against PBS, the total MAb yield was determined using a NanoDrop spectrophotometer.
Polyclonal anti-DLP antibodies were raised in adult mice by subcutaneous immunization
with 100μg purified DLPs. A boost immunization of 50μg DLPs was given subcutaneously 14
days later. Serum samples from immunized mice were collected 28 days after the initial immu-
nization, and any infection challenge experiments were also performed at this time.
VP6-specific IgG was purified from human pooled IgG (Sanquin, The Netherlands) by
affinity chromatography. DLPs were conjugated to agarose beads using AminoLinkTM Plus
Immobilisation Kit (ThermoFischer Scientific), then antibodies purified according to manu-
facturer’s instructions.
Generation of mouse human-chimeric h7D9 MAbs was achieved by synthesizing cDNA
fragments encoding 7D9 heavy chain variable regions (Genscript Inc, USA) that were sub-
cloned in frame with the constant region of the human IgA1 or IgG1 heavy chain (HC) in the
expression vectors pFUSEss-CHIg-hA1 and pFUSEss-CHIg-hG1 (Invivogen, USA). Similarly,
a cDNA fragment encoding the 7D9 light chain (LC) variable region was synthesized and sub-
cloned (Genscript) into pFUSEss-CLIg-hκ (Invivogen, USA). h7D9 IgA1 or IgG1 HC vectors
were then transiently co-transfected with the LC vector into the Expi293 cell line using the
Expi293 transfection kit (ThermoFisher, USA). The h7D9 IgG1 MAbs were purified using a
CaptureSelect-CH1 specific column (ThermoFisher) while the h7D9 IgA1 MAb was purified
using a CaptureSelect-IgA specific column (ThermoFisher). Monomeric fractions were iso-
lated by size exclusion chromatography using a Superdex 200 Increase 30/300 column and
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concentrated on AmiconUltra 100K spin columns (Millipore). Purified proteins were analysed
by SDS-PAGE (ThermoFisher, USA). h9C12-IgG1-WT was produced as described [31].
Rotavirus infection of mice
Neonatal BALB/c mice were infected with 5 x 104 FFFU of the Epizootic Diarrhoea of Infant
Mice (EDIM) virus in 10μl total volume by oral gavage. Neonatal C57Bl/6 mice were infected
with 1.5 x 103 FFU of murine rotavirus strain EMcN. Stool samples were collected by gentle
palpation of pup abdomens once daily for 4 days. Samples were pooled, diluted 1:10 in PBS
and clarified by centrifugation at 8000 x g for 5 minutes. Rotavirus infectivity was then quanti-
fied by fluorescent focus forming assay in MA104 cells and aliquots were stored at -80˚C until
use.
TRIM21 knockout BALB/c mice were generated by back-crossing TRIM21KO C57Bl/6
mice [27] x wild type BALB/c mice for the first round, selecting for TRIM21 heterozygous and
back-crossing for 7 more rounds to BALB/c selecting after each round TRIM21+/-. After 8
rounds, TRIM21 heterozygous mice were crossed to select pure TRIM21KO on Balb/c back-
ground. Adult wild type or TRIM21 knockout Balb/c mice were infected with 5 x 104 FFU
EDIM in 50μl total volume. Adult wild type or FcRn knockout C57Bl/6 mice (purchased from
JAX) were infected with 15 FFFU EMcN in 50μl total volume. Faeces were collected once daily
for the 7 days following infection and stored at -20˚C until further processing. Faecal pellets
were diluted 1:10 in Earles Balanced Salt solution by weight, and clarified by centrifugation at
8000 x g for 5 minutes. Faecal levels of murine rotavirus virus were quantified using a commer-
cial mouse rotavirus antigen ELISA kit (Cusabio) according to the manufacturer’s
instructions.
Serum samples were obtained via centrifugation of clotted blood samples collected either
from saphenous venipuncture or cardiac puncture.
Ethics statement
All mouse infection experiments were conducted in accordance with the 19.b.7 moderate
severity limit protocol and Home Office Animals (Scientific Procedures) Act (1986). All ani-
mal work was licensed under the UK Animals (Scientific Procedures) Act, 1986 and approved
by the Medical Research Council Animal Welfare and Ethical Review Body.
ELISAs
Ninety-six-well polystyrene microtitre plates (Microlon1, Greiner) were coated overnight at
4˚C with 100ng purified DLPs/well in carbonate/bicarbonate buffer. Plates were washed three
times with 0.05% Tween 20 in phosphate buffered saline (PBS-T) before blocking with 5%
skimmed milk-PBS-T for 1 hour at 37˚C, followed by three PBS-T washes. Plates were then
incubated for 1 hour at 37˚C with dilutions of each serum sample in duplicate in 5% skimmed
milk-PBS-T. After three washes with PBS-T, 50μl of horseradish peroxidase (HRP)-conjugated
anti-mouse IgG antibody, or HRP-conjugated anti-mouse IgA (Bio-Rad) diluted 1:1000 in 5%
skimmed milk PBS–T, were added to each well and incubated at 37˚C for 1 hour. The plates
were washed four times with PBS-T, and bound antibody was detected by addition of 50μl tet-
ramethylbenzidine (TMB, Invitrogen) followed by incubation at room temperature for 10
minutes. The reaction was stopped with 1M H2SO4 and the optical density (OD) was read at
450 nm with a microplate reader (PHERAstar). The background signal for each sample was
determined by measuring the OD450 of serum samples incubated with carbonate/bicarbonate
buffer alone.
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For sandwich ELISAs, rotavirus polyclonal antibody (PA1-85845, Thermo Fisher Scientific)
was coated onto plates at 20ug/μl in carbonate/bicarbonate buffer overnight at 4C. Plates were
washed three times with PBS-T, then cell lysate from MA104 cells infected with SA11 or unin-
fected control were added to plates at 20ug/μl for 4 hours. Plates were then washed three times
with PBS-T before blocking with 5% skimmed milk-PBS-T. The remainder of the protocol was
as described above.
To study recombinant antibodies produced, ELISAs were performed with DLPs as
described above, with the following modifications; bound recombinant antibodies were
detected using either an alkaline phosphatase (AP) conjugated anti-human Fc-antibody from
goat (#A9544), Sigma-Aldrich, USA) or AP-conjugated anti-human IgA F(ab)2
(#SAB3701226, Sigma Aldrich, USA). Binding was visualized by addition of phosphatase sub-
strate (Sigma Aldrich) and the 405 nm absorption spectrum was measured using a Sunrise
spectrophotometer (TECAN, Austria).
Statistics
To compare differences between two groups of values, unpaired T-tests were performed. P val-
ues<0.05 were considered significant. Analyses were conducted using GraphPad Prism.
Results
Development of an intracellular neutralisation assay
To study the interaction between rotavirus VP6 protein and anti-VP6 antibodies intracellu-
larly, an assay was developed to enable rapid introduction of antibody into the cytosolic com-
partment of cells. Serially diluted anti-VP6 mouse IgA monoclonal antibody (MAb) (800ng–
50ng) or a non-specific control antibody (800ng) were electroporated into MA104 cells using
the Neon Transfection System. Cells were then infected with rotavirus overnight, and the
degree of virus neutralisation was measured by fluorescent focus forming reduction assay. Fig
1A and S1A Fig presents images from a typical neutralisation assay as captured by a Nikon
Eclipse Ti microscope, and Fig 1B shows quantification of images from triplicate wells using
Nikon NIS-elements analysis software. The relative level of infection was calculated based on
the number of foci in the non-specific control well. Confocal microscopy confirmed that elec-
troporation of anti-VP6 MAb resulted in rapid co-localisation with DLPs within 1 hour of
rotavirus infection (Fig 1C, S1B Fig).
Comparison of two anti-VP6 IgA MAbs, 7D9 and 2C5, demonstrated that both were unable
to neutralise rotavirus if incubated with virus extracellularly according to standard protocols,
but inside cells both MAbs potently neutralised virus in a dose-dependent manner (Fig 1D).
Conversely, MAbs directed against the outer capsid protein VP4 (1A9 and 7A12) were unable
to neutralise rotavirus after electroporation into cells (Fig 1E), whereas previous studies had
shown they can neutralize RV extracellularly [32].
Characterisation of polyclonal antibodies mediating intracellular
neutralisation
To determine whether it is the specific epitope specificity of 7D9 and 2C5 that allows intracel-
lular neutralization or if polyclonal antibodies are similarly effective, we raised VP6 antisera by
immunizing mice with purified DLPs (S2 Fig). Native sera from immunized mice or unimmu-
nized controls were then electroporated into cells. Fig 2A demonstrates that effective intracel-
lular neutralisation is mediated by anti-DLP antibodies. To test whether this neutralization is
physiologically relevant and capable of providing protective immunity in vivo we performed
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infection and re-challenge experiments. Importantly, the data show that mice immunized with
DLPs were protected from subsequent challenge with Epizootic Disease of Infant Mice
(EDIM) virus (Fig 2B), with statistically significant differences in viral loads detected on days
3–6 post infection. This confirmed the importance of anti-VP6 antibodies in vivo.
We observed that the mice immunized with DLPs and protected from EDIM produced a
significant IgG anti-VP6 response (Fig 2C). Conversely, no significant difference was observed
between IgA titres in naïve and immunized mice. It was expected that induction of IgG was
Fig 1. Intracellular neutralisation assay. (A) Images of rotavirus-infected cells following electroporation of anti-VP6 MAb.
Rotavirus-infected cells were stained with sheep polyclonal anti-rotavirus antibody and subsequently Alexa-Fluor
488-conjugated anti-sheep Ig. Scale bar 200μm (B) Fluorescent foci in (A) captured on a Nikon Eclipse Ti microscope were
quantified by NIS analysis software. (C) Confocal images of a rotavirus-infected murine embryonic fibroblast cell 1 hour post
infection in the presence of electroporated anti-VP6 Mab, scale bar 10μm. (D) Comparison of extracellular versus intracellular
neutralisation for two anti-VP6 MAbs, 7D9 and 2C5. (E) Testing for intracellular neutralisation mediated by MAbs recognising
VP4 (7A12 and 1A9).
https://doi.org/10.1371/journal.ppat.1008732.g001
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due to the subcutaneous immunization route, but this raised the question of whether VP6-spe-
cific IgG or IgA were mediating the protection observed.
We reasoned that if VP6-specific IgG is important for protecting against rotavirus infection
in natural infections, then it should neutralize rotavirus via the intracellular neutralization
assay. DLPs were conjugated to agarose beads, and used to affinity purify VP6-specific anti-
body from IgG pooled from healthy human donors (Sanquin, The Netherlands). This demon-
strated that VP6-specific IgG is produced in response to rotavirus infection in humans,
confirming previous reports that have identified VP6-specific IgG in naturally infected people
[4,21,22]. Importantly, this VP6-purified human IgG efficiently neutralized rotavirus (strain
SA11) in the intracellular neutralization assay conducted in MA104 cells (Fig 2D).
Mechanism of intracellular neutralisation by IgG
To directly compare the relative potency of VP6-specific IgA and IgG, we produced recombi-
nant class-switched 7D9 antibodies with either a human IgA1 or IgG1 heavy chain (hereafter
Fig 2. Analysis of VP6-specific polyclonal immune responses in mice and humans (A) Intracellular neutralisation of
rotavirus infection by anti-DLP polyclonal serum versus control serum electroporated into cells. (B) Faecal antigen shedding as
detected by ELISA on days 1–7 post infection in mice immunized with DLPs 2 and 4 weeks prior to infection, compared to
naive mice (4–5 mice per group). (C) ELISAs to detect IgG and IgA polyclonal antibodies raised by DLP immunization in
mice, each symbol representing one mouse. (D) Intracellular neutralisation of rotavirus (strain SA11) by VP6-specific IgG
purified from human pooled IgG in MA104 cells. For all graphs, error bars represent standard error, ���� p =< 0.0001, �� p =
< 0.01, � p =< 0.05, NS not significant.
https://doi.org/10.1371/journal.ppat.1008732.g002
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referred to as hIgA and hIgG). Both monomeric antibodies were able to bind to DLPs in
ELISA (Fig 3A and 3B), with significantly higher absorbance at every antibody concentration
compared to non-specific mAb 9C12 as shown in Fig 3A. Previous studies using anti-VP6 IgA
monoclonal antibodies have shown that blockade of mRNA egress from DLPs is a mechanism
by which neutralisation can occur [7,16,18,33]. If the sole activity of 7D9 was pore blockade, it
was theorized that the Fc region would have no effect on neutralisation within cells. To investi-
gate this, mouse-human chimeric IgA 7D9 and IgG 7D9 were electroporated into MA104 cells
and intracellular neutralisation measured (Fig 3C). It was found that the IgG Fc region signifi-
cantly enhanced neutralisation, with statistically significant differences identified at each con-
centration studied.
The intracellular Fc receptor TRIM21 is known to bind IgG with a substantially higher
affinity than IgA [34]. Therefore, we hypothesised that the enhanced intracellular neutralisa-
tion mediated by VP6-specific IgG could be due to efficient recruitment of TRIM21. This Fc
receptor is an E3 ligase that undergoes autoubiquitination when activated and targets the
virus-antibody complex for degradation by the proteasome [19]. TRIM21 knockout MA104
cells were generated using CRISPR technology (S3 Fig), then used to evaluate intracellular neu-
tralisation in the electroporation assay. There was no TRIM21-dependent component to intra-
cellular neutralisation by 7D9 IgA (Fig 4A), but when using 7D9 IgG, a clear
TRIM21-dependent phenotype was apparent (Fig 4B). Next, the Fc region of 7D9 IgG was
engineered to prevent TRIM21 binding through the introduction of an H433A mutation pre-
viously shown to ablate TRIM21:IgG binding in vitro and their interaction in cells [31,35].
This mutation significantly decreased intracellular neutralisation mediated by IgG (Fig 4C).
We also demonstrated a small TRIM21-dependent effect on intracellular neutralisation when
low concentrations of sera from mice immunized with DLPs were electroporated into cells (S4
Fig). We showed that this neutralisation was partially diminished when cells were pretreated
with 1μM of the proteasomal inhibitor MG132, supporting the hypothesis that proteasomal
degradation is required for this neutralisation mechanism.
To extend these findings in vivo, wild type and TRIM21 knockout BALB/c mice were
immunized with DLPs on days 0 and 14, then challenged with EDIM virus on day 28. Shed-
ding of EDIM virus was then measured by faecal antigen ELISA. Viral shedding 3 days post
Fig 3. Production and characterization of VP6-specific recombinant monoclonal antibodies. (A) Mouse-human chimeric 7D9 hIgG binds to DLPs by
ELISA while control antibody (9C12) does not. (B) Mouse-human chimeric 7D9 hIgA binds to DLPs by ELISA. (C) Intracellular neutralisation of rotavirus by
VP6-specific 7D9 with human IgG1 Fc region compared to IgA1 region electroporated into cells. For all graphs, error bars represent standard error, ���� p =<
0.0001, ��� p =< 0.001, �� p =< 0.01, � p =< 0.05, NS not significant.
https://doi.org/10.1371/journal.ppat.1008732.g003
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infection is shown in Fig 4D; whilst immunization of wild type mice with DLPs significantly
reduced peak viral shedding at day 3 (p = 0.0007, unpaired t test), immunization of TRIM21
knockouts did not (p = 0.211). Moreover, there was a significant difference when comparing
across genotypes with immunized knockouts shedding more virus on day 3 than wild type
equivalents (p = 0.020). Virus shedding by naïve mice on day 3 post-infection was comparable
for both wild type and TRIM21 knockout mice, confirming that TRIM21 antiviral activity is
antibody-dependent. By 4 days post-infection the DLP-immunized TRIM21 knockout mice
had controlled virus shedding to a similar degree to that of the wild type mice (Fig 4E).
VP6-specific IgG protects against rotavirus infection in vivo
While the predominance of IgG in the anti-VP6 response during DLP immunization was sug-
gestive of its importance, we sought direct evidence of its physiological role by using a mouse
model with reduced IgG but normal levels of other antibody isotypes. Mice deficient in the
neonatal Fc receptor (FcRn) were selected for this purpose, as the absence of FcRn reduces
Fig 4. Mechanisms of antibody-mediated intracellular neutralisation. (A) Intracellular neutralisation of rotavirus by VP6-specific IgA in wild
type (WT) and TRIM21 knockout (TRIM21KO) MA104 cells. (B) Intracellular neutralisation by VP6-specific IgG in WT and TRIM21KO
knockout MA104 cells. (C) Intracellular neutralisation by WT or non-binding TRIM21 IgG (H433A). (D) Amounts of EDIM virus shedding three
days post infection as detected by faecal antigen ELISA in naïve and pre-DLP-immunized, WT (9–10 mice per group) as well as TRIM21KO mice
(5 mice per group). (E) EDIM shedding on days 1–7 post infection in WT and TRIM21KO BALB/c mice pre-immunized with DLPs. Horizontal
lines represent mean and standard error, ��� p =< 0.001, � p =< 0.05, NS not significant.
https://doi.org/10.1371/journal.ppat.1008732.g004
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antibody IgG levels by decreasing its half-life from 6–8 days to approximately 1 day [36]. In
contrast to other antibody-deficient models, however, there is no change in antibody diversity
or in B cell compartments [36,37].
WT and FcRn knockout mice (five mice per group) were immunized with DLPs on days 0
and 14, then challenged with EDIM virus on day 28. As the FcRn knockout mice used were on
a C57Bl/6 background, we infected mice with an alternative murine rotavirus strain known to
readily infect C57Bl/6 wild type mice (EMcN [38]). Fig 5A shows that following immunization,
FcRn knockout mice generally had lower levels of serum IgG antibody than their wild type
counterparts, although this difference was not statistically significant (unpaired t test
p = 0.055). Importantly, when challenged with EMcN murine rotavirus, FcRn knockout mice
were significantly less able to control virus shedding than wild type mice (Fig 5B). This was sta-
tistically significant on both days 4 and 5 post infection (unpaired t-test, p< 0.0001 and
p = 0.0217 respectively), while infection levels in naïve mice of each genotype were comparable
at these time points (Fig 5C).
Fig 5. Rotavirus infection in FcRn deficient mice. (A) DLP-specific antibodies in serum of naïve and DLP-
immunized, WT and FcRnKO mice (5 mice per group, each symbol representing one mouse). (B) Faecal antigen
shedding on days 0–6 post infection as detected by ELISA in the mice pre-immunized with DLPs, comparing WT with
FcRn knockout (FcRnKO) mice. (C) Amounts of EMcN virus shedding in faeces of the naïve and DLP-immunized, WT
and FcRnKO mice, days 4 and 5 of experiment shown in panel (B). Horizontal lines represent mean and standard error,
���� p =< 0.0001, � p =< 0.05, NS not significant.
https://doi.org/10.1371/journal.ppat.1008732.g005
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Discussion
Here we describe a new intracellular neutralization assay that allows direct comparison of neu-
tralizing antibodies regardless of isotype. We have used the intracellular neutralization assay in
combination with murine models of rotavirus infection to illustrate that VP6-specific IgGs
have an important physiological role in neutralising rotavirus. The ability to study the interac-
tions between antibodies and viruses like rotavirus inside cells has classically relied on trans-
well systems or lipid-based transfection reagents [7,25]. Whereas the former approach
presents a physiologically relevant system, it is relatively time-consuming to establish, and the
efficiency of transfection systems is low. The electroporation-based intracellular neutralisation
assay allows antibodies to be introduced directly into the cytoplasm rapidly and efficiently,
supports high-throughput analyses and can be used with both MAbs and polyclonal antisera.
Whereas the focus of our study has been centered on rotaviruses, the electroporation meth-
odology described can be used for other viruses that may be targeted by antibodies inside cells.
For example, a number of MAbs specific for viral proteins only exposed intracellularly have
been characterised for both influenza viruses and lymphocytic choriomeningitis virus [39–41].
These antibodies are non-neutralising in vitro, but in vivo are able to mediate protection from
infection. Using the intracellular neutralisation assay to study the activity of these antibodies
inside cells, and being able to easily measure their presence in clinical samples may be highly
beneficial for future basic and translational research.
The intracellular neutralisation assay has demonstrated that the mechanisms by which
intracellular antibodies are neutralising rotavirus are multifactorial. It has previously been
shown that neutralisation can occur through blockade of VP6 pores of DLPs through which
viral mRNAs egress, or through alteration of the pore structure when binding adjacently
[7,16,18,33]. This phenomenon does not rely on any specific activity of the Fc region of anti-
bodies, and indeed it is known than VP6-specific nanobodies can protect against rotavirus
infection [8,42,43]. However, a recent study that examined the effect of fusing an IgG1 Fc
domain fragment to a VP6 nanobody did show enhanced neutralisation [44], thus supporting
the conclusion that multiple mechanisms are at play. We therefore sought to explore whether
cellular factors could enhance this neutralisation, specifically the intracellular antibody recep-
tor TRIM21. This was achieved using TRIM21 deficient cell lines, recombinant antibodies
unable to bind TRIM21, and finally TRIM21 deficient mice. TRIM21 is an E3 ubiquitin ligase
that is activated when it binds the Fc portion of cytosolic antibodies bound to virus, catalysing
auto-ubiquitination. This ubiquitination targets the virus-antibody complex to the proteasome
for degradation [19]. TRIM21 has been extensively characterised in the context of non-envel-
oped viruses with a single capsid layer, such as adenovirus and rhinovirus [45]. Non-entry
blocking antibodies bound to the virus reach the cytoplasm via the viruses’ natural entry path-
way. However, we have now shown that TRIM21 can drive antibody-mediated neutralisation
when the antibodies are most likely entering the cytoplasm independently of incoming virus.
In summary, we propose that VP6-specific IgG are able to block viral replication via two differ-
ent mechanisms; blockade of DLP pores as previously shown by numerous studies, and also
TRIM21-mediated proteasomal degradation of subviral particles. It is predicted that TRIM21
activity is most valuable at low levels of VP6-specific antibody, as previous work has shown
that TRIM21 can become activated by as few as two antibodies [20], whereas effective pore-
blockade may require a higher antibody concentration. The involvement of TRIM21 in anti-
VP6 mediated protection may explain why immunisation of some species with DLPs does not
always provide protection. TRIM21 is an interferon stimulated gene (ISG) and its expression is
induced by interferon, meaning that the presence of anti-VP6 antibodies may not be enough.
To be protective there may also have to be an accompanying inflammatory response.
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Multiple lines of evidence indicate that rotavirus-specific IgG is important for immune pro-
tection in several species. In a primate model, passive transfer of IgG protected against rotavi-
rus infection [46], and in rabbits, IgG induced by vaccination with rotavirus-like-particles was
protective against oral challenge with rotavirus [47]. In humans serum IgG levels correlate
with protection in a number of studies [48], and furthermore, IgA-deficient individuals are
still able to recover from rotavirus infection [49]. Rotavirus infection of FcRn deficient mice
has also been performed, as a means of reducing total IgG levels in vivo [50]. FcRn functions as
a recycling receptor, binding to IgG at low pH in endosomes and rescuing IgG from degrada-
tion by the lysosomes. IgG titres in mice lacking FcRn are therefore approximately 30 times
lower than in wild type mice [26]. While previous studies in FcRn deficient mice have revealed
prolonged rotavirus shedding compared to wild type mice, these experiments were performed
in naïve animals and the resulting primary antibody response will have contained entry neu-
tralizing antibodies against the VP4 and VP7 proteins of the outer capsid [50]. To study the
importance of VP6-specific IgG separately from all rotavirus-specific IgG, we tested FcRn-defi-
cient mice that were immunized with DLPs. As IgA levels remain unchanged in FcRn deficient
mice, the prolonged viral shedding we observed can be directly attributable to VP6-specific
IgGs.
As VP6 is only exposed post-cell entry, our findings indicate that protective IgG must be
entering epithelial cells independently of viral particles. IgA is known to be transported from
the basolateral to the apical side of epithelial cells via pIgR-mediated transcytosis. IgA-contain-
ing endosomes fuse with virus-containing endosomes during transcytosis, allowing antibody-
virus complexes to form. IgG can also be transported across epithelial cells by FcRn, following
fluid-phase pinocytosis on the basolateral side [51,52]. We suggest that this is the means by
which VP6-specific IgG can co-localise with a protein only exposed intracellularly. During
trafficking by FcRn, analogously with pIgR trafficking, IgG-containing endosomes fuse with
virus-containing endosomes. The antibodies bind DLPs within the endosome then accompany
the virus into the cytosol.
While FcRn is known to be important for IgG homeostasis, we speculate that it may also
enhance co-localisation of VP6-specific IgG with DLPs inside cells. This would be analogous
to the proposed mechanism by which pIgR traffics anti-VP6 IgAs to virus-containing com-
partments during IgA-mediated neutralization [24,25]. FcRn localizes intracellularly in endo-
somes positive for Rab5 and EEA1 [53,54], which are the same intracellular compartments
that rotavirus reaches upon entry into cells [55]. Following entry of IgG from the basolateral
side of epithelia into pinocytic vesicles, IgG subsequently binds to FcRn in the endosomes as
they acidify. All known strains of rotavirus reach maturing endosomes before uncoating their
outer capsid [55], thus they would be expected to be present in the same cellular compartments
as FcRn when binding to IgG occurs. We propose that FcRn could enhance the ability of
VP6-specific IgG to meet DLPs, without which IgG is sorted into lysosomes. Further work on
the potential role of FcRn supporting VP6-specific IgG binding to uncoated rotavirus particles
in endosomes is warranted.
The finding that VP6-specific IgG can be protective in a mouse model of rotavirus infection
raises questions regarding the use of current assays to establish correlates of protection for
rotavirus vaccines. Moreover, our data highlight multiple mechanisms by which anti-VP6 anti-
bodies can provide this protection. The most widely used correlate of protection for rotavirus
in humans following vaccination is rotavirus-specific serum IgA titre [56,57]. This measure is
often considered to be imperfect, with poor correlation between IgA seroconversion and pro-
tection from severe rotavirus-induced gastroenteritis in several studies [56,58]. We propose
that omitting to measure rotavirus-specific IgG could be part of the explanation as to why
serum IgA titres are not an optimal correlate of protection. Moving forwards, it is important
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that the role of VP6-specific IgG is evaluated for its ability to contribute to protection from
rotavirus disease in the context of human infections and vaccination.
Supporting information
S1 Fig. Microscopy of electroporated cells. A) Nuclei stained with Hoechst 33342 from the 4
different wells presented in Fig 1A, scale bar 200μm. B) Extended Fig 1C showing additional
controls used for confocal images; only in the presence of both SA11 rotavirus and anti-VP6
Mab is co-localization observed. Scale bar 10μm.
(TIFF)
S2 Fig. Purity of DLP preparation. A) Image of viral bands after centrifugation at 110,000 x g
for 18 hours on a CsCl gradient. B) Coomassie blue stained agarose gel of viral bands collected
separately by needle puncture, demonstrating different protein composition of triple layered
particles (TLP) and double layered particles (DLP). C) Western blot confirmation of the speci-
ficity of antibodies in sera from mice immunized with DLP in comparison with antibodies
generated by mice infected with EDIM rotavirus; MA104 cells infected with rotavirus for 16
hours were lysed in SDS-PAGE loading buffer, the lysate separated by SDS-PAGE, then
stained with Coomassie blue or western blotted with mouse sera.
(TIFF)
S3 Fig. Confirmation of TRIM21 knockout of MA104 cells by CRISPR. A) Western blot of
whole cell lysate of one wild type (WT) MA104 clone and three TRIM21 knockout (KO)
MA104 clones. B) Western blot showing ability of WT cells to degrade IKK when anti-IKK
antibody is electroporated into cells (‘Trim-Away’), whereas no degradation of IKK is medi-
ated by TRIM21 KO cells (clone b).
(TIFF)
S4 Fig. TRIM21-dependent intracellular neutralisation by DLP-specific polyclonal sera. A)
Intracellular neutralisation in wild type (WT) and TRIM21 knock out (TRIM21KO) cells by
serially diluted anti-DLP polyclonal serum. B) Intracellular neutralisation of rotavirus by undi-
luted anti-DLP polyclonal serum and control serum in the presence of 1μM MG132. For both
graphs, error bars represent standard error, � p =< 0.05.
(TIFF)
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